获取途径

作者

黄 振 韩建军

作者单位

山东省肿瘤防治研究院(山东省肿瘤医院)，山东第一医科大学(山东省医学科学院)，山东 济南

刊名

Advances in Clinical Medicine

年份

2026

卷号

Vol.16 No.5

页码

1488-1496

ISSN

2161-8712

关键词

肝细胞癌 介入治疗 经动脉化疗栓塞 肝动脉灌注化疗 靶向治疗 免疫治疗 Hepatocellular Carcinoma Interventional Therapy Transarterial Chemoembolization Hepatic Arterial Infusion Chemotherapy Targeted Therapy Immunotherapy

摘要

Hepatocellular carcinoma is the most common histological subtype of primary liver cancer. Owing to the lack of specific symptoms at the early stage, many patients are diagnosed at an intermediate or advanced stage and consequently lose the opportunity to undergo potentially curative treatments such as surgical resection, liver transplantation, or local ablation. Interventional therapy has long played an important role in the multidisciplinary management of HCC, among which transarterial chemoem...更多

Hepatocellular carcinoma is the most common histological subtype of primary liver cancer. Owing to the lack of specific symptoms at the early stage, many patients are diagnosed at an intermediate or advanced stage and consequently lose the opportunity to undergo potentially curative treatments such as surgical resection, liver transplantation, or local ablation. Interventional therapy has long played an important role in the multidisciplinary management of HCC, among which transarterial chemoembolization and hepatic arterial infusion chemotherapy are of substantial value in controlling intrahepatic lesions and reducing tumor burden. In recent years, with the continuous development of targeted therapy and immunotherapy, interventional therapy combined with targeted therapy and immunotherapy has gradually become a major focus of research. Available evidence suggests that interventional therapy not only exerts a direct tumor-reducing effect, but may also promote antigen release and modulate the tumor microenvironment, thereby creating favorable conditions for subsequent systemic treatment. Targeted therapy and immunotherapy may further enhance antitumor efficacy. At present, TACE- or HAIC-based combination strategies with targeted therapy and immunotherapy have shown promising application prospects in patients with unresectable HCC, HCC with high tumor burden, and selected patients requiring conversion therapy. This article reviews the theoretical basis, clinical research progress, and clinical value of interventional therapy combined with targeted therapy and immunotherapy for HCC, with the aim of providing a reference for clinical practice.收起

文献类型

期刊

浏览量

6